The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ethics Forum: Medical Ethical Considerations for COVID-19

Ethics Forum: Medical Ethical Considerations for COVID-19

June 8, 2020 • By David Y. Chen, MD, PhD, & Eric J. Gapud, MD, PhD, on behalf of the ACR Committee for Ethics & Conflicts of Interest

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Modern principles governing the actions of individuals and institutions in patient care are often centered around four core principles formulated by Beauchamp and Childress: respect for autonomy, beneficence, non-maleficence and justice.1 Situational contexts in which these principles are in tension compel their reprioritization. And catastrophic externalities, such as the COVID-19 pandemic, impose special circumstances that must be considered to enable providers to discharge their duty to provide care in accordance with these principles.

You Might Also Like
  • Ethics Forum: The Ethical Considerations of Prior Authorization
  • Considerations for Rheumatologists on Twitter: Ethics Forum
  • Ethics Forum: The Ethical Challenges of Recruiting Patients for Clinical Trials
Explore This Issue
July 2020

SARS Coronavirus-2 (SARS-CoV-2), the novel infectious agent responsible for COVID-19, was first identified in human patients only at the end of 2019. As of June 3, 6,445,457 people worldwide have been infected, and 381,175 have died, corresponding to a mortality rate of slightly over 7% in tested-positive cases.2 Roughly a third of known cases are in the U.S., and 106,696 patients have died here, despite our advanced medical science, technology and capabilities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The unusual infectivity of SARS-CoV-2 coupled with a high burden of asymptomatic transmission and the complex pathophysiology of this novel virus have exposed limitations and vulnerabilities in our technology, resources and healthcare delivery infrastructure.

Provider redeployments and the implications of drug shortages exacerbated by repurposing are two high-profile examples of the many important and unexpected issues increasingly faced by rheumatologists as a result of these stresses on our system. Here, we explore the ethical conflicts and obligations that pertain in these specific cases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Prescribing Stewardship

The COVID-19 pandemic has placed rheumatologists in the unique and unexpected position of prescribing stewardship. Increasing evidence indicates some poor outcomes in COVID-19 cases may be due to late immune-mediated sequelae of the viral infection. Clinicians and scientists are recognizing that a number of cytokine interference and immune-modulation agents used in standard rheumatology practice may be beneficial for critically ill COVID-19 patients. Consequently, rheumatologists increasingly find themselves the most common prescribers of known drugs with off-label, life-saving potential.

The initial enthusiasm for hydroxychloroquine for use against COVID-19 resulted in a sudden, high-volume diversion of the drug and threatened access for patients with established rheumatologic indications for their use. This sudden interest was based on encouraging results from small, uncontrolled studies of COVID-19 patients in China and France, particularly the one described by Gautret and colleagues in mid-March 2020.3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Within days, shortages were reported around the country. The national supply of hydroxychloroquine was already particularly vulnerable given its history as a drug with relatively few regular manufacturers and price spikes. The U.S. Food & Drug Administration also authorized emergency use of hydroxychloroquine to treat COVID-19 patients for whom a clinical trial was not available by the end of March 2020, although clinical evidence of effectiveness remained inconclusive. As a result, patients with conditions for which hydroxychloroquine has proved beneficial were placed at risk of being without medication.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Ethics Tagged With: COVID-19, Ethics ForumIssue: July 2020

You Might Also Like:
  • Ethics Forum: The Ethical Considerations of Prior Authorization
  • Considerations for Rheumatologists on Twitter: Ethics Forum
  • Ethics Forum: The Ethical Challenges of Recruiting Patients for Clinical Trials
  • Ethics Forum: Who Did You Vote For? Is a Discussion of Politics in the Medical Office the Taboo It Once Was?

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)